Steve Hong – CEO; Tony Lim – COO & Vice President, Lemon Healthcare,…
Steve Hong, CEO, and Tony Lim, vice president & COO of Lemon Healthcare, lift the lid on the new streamlined hospital data services they are offering, and the benefits to…
Bioneer Corp., founded in 1992 as the first bio-venture in South Korea, is moving forward to a full-fledged molecular biotechnology company on the strength of the R&D infrastructure and intellectual properties.
Since beginning the home production of synthetic oligonucleotides and PCR enzymes with its proprietary technology for the first time in Korea, Bioneer has continuously built up expertise in molecular diagnostics and RNAi therapeutics. Bioneer is currently providing total solutions for molecular diagnostics in various disease areas through an integrated platform of reagents, instruments and analysis software. Bioneer’s SAMiRNA™ is a new paradigm of RNAi therapeutics in terms of being a much more efficient carrier compared to the conventional methods to deliver siRNA to the inside of a target cell.
Bioneer has vertically integrated genomic technology-based businesses, which provides competitive advantages in the market such as price competitiveness, product development efficiency and a high level of control. Today, Bioneer is operating businesses in the following three domains: Research-use products in genomics, biotechnology, molecular biology, etc.; Molecular diagnostic reagents, instruments and software; New development based on RNAi.
Contact details
Webpage: www.bioneer.com
Address: 8-11, Munpyeongseo-ro, Daedeok-gu, Daejeon 306-220, Republic of Korea
Tel: +82-42-930-8777
Fax: +82-42-930-8688
Email: sales@bioneer.com
Steve Hong, CEO, and Tony Lim, vice president & COO of Lemon Healthcare, lift the lid on the new streamlined hospital data services they are offering, and the benefits to…
The French-Korean Chamber of Commerce and Industry (FKCCI) has grown rapidly in the last decade, both in terms of members and revenues. Its managing director, Stella Yoon, explains how the…
YongBum Choi, general manager of Ferring Korea, explains how he plans to foster the Ferring values in the local affiliate. Mr Choi also breaks down the stigmas associated with assisted…
The Pharmaceutical Strategy Institute (PSI) is a Korean consulting firm helping local biotech companies reach success by providing strategic and legal counsel all along the value chain. Its founder &…
James Jungkue Lee, founder and CEO of Bridge Biotherapeutics, explains his strategy for risk mitigation in running a virtual biotech start-up. He also offers his insights into the company’s partnership…
Dr Jin Hyoung Kang, president of the Cancer Study Group comments on the scope for oncology drug development in Korea, and the issues resulting from the structure of Korea’s healthcare…
Quegen Biotech is a company focusing on manufacturing beta-glucan for use in a range of healthcare products, from hangover cures to oncology treatments. In this interview, Dr Jong Dae Lee…
Pil Soo Oh has been the managing director of Lundbeck Korea since the establishment of the affiliate in 2002. Mr Oh offers his insights into Lundbeck’s footprint in Korea, their…
Jong-Gu Chung, general manager of CooperVision Korea, lifts the lid on his strategy to establish their position in the Korean market for contact lenses. Chung also gives his assessment of…
Established in 1986, the KDRA is Korea’s leading new drug research and development special corporation, established under the Ministry of Science and ICT and composed of 350 members. Its executive…
LG Life Sciences is one the early pioneers of innovative drug development in Korea with a diversified portfolio of chemical drugs, vaccines, biosimilars, biologics, and dermo-cosmetics. Its president, Dr Son,…
South Korean heavyweight Daewoong Pharmaceutical saw record sales in 2018, but did see a decrease in its EBITDA figures. To ensure its future profitability, the company has decided to invest…
See our Cookie Privacy Policy Here